Placebo News and Research

RSS

Pfizer announces results from Phase 3 study of ALO-02 in patients with chronic low back pain

Pfizer Inc. (NYSE: PFE) announced today top-line results from a Phase 3 study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic low back pain.

24 Jan 2014

Use of twice-daily pill could turn deadly blood cancer into highly treatable disease

Use of a twice-daily pill could turn a deadly blood cancer into a highly treatable disease, according to scientists at Weill Cornell Medical College who led a multinational research team.

24 Jan 2014

Prosonix announces positive top-line results from PSX1002 Phase 2 study for COPD treatment

Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, announces positive top-line results from its Phase 2 clinical study with PSX1002 in patients with moderate to severe chronic obstructive pulmonary disease.

23 Jan 2014

New drug helps children and young adults who have severe pain from sickle cell disease

Saint Louis University researchers are studying whether ReoPro® (abciximab), a drug currently given to heart patients undergoing angioplasties to open blocked arteries, also could help children and young adults who have severe pain from sickle cell disease.

23 Jan 2014

Hydroxytyrosol in olive oil may help reduce risk of breast cancer

A major component of olive oil, hydroxytyrosol, is the subject of a Houston Methodist study of women who are at increased risk of developing breast cancer. The study focuses on the changes in breast density after one year of treatment and is the first of its kind in the United States.

23 Jan 2014

EnVivo Pharmaceuticals starts encenicline Phase 3 study in patients with Alzheimer's disease

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel therapies for central nervous system diseases, today announced it has initiated COGNITIV AD, a Phase 3 clinical program evaluating its novel alpha-7 (α7) potentiator, encenicline-hydrochloride (EVP-6124), in patients with Alzheimer's disease. The program is being conducted under a Special Protocol Assessment agreement with the FDA.

22 Jan 2014

Study shows clinical trials used by FD to approve new drugs vary widely in characteristics

Clinical trials used by the Food and Drug Administration (FDA) to approve new drugs between 2005 and 2012 vary widely in their characteristics, according to a study in the January 22/29 issue of JAMA.

22 Jan 2014

Potentially preventable deficiencies account for significant delays in approval of new drugs by FDA

Several potentially preventable deficiencies, including failure to select optimal drug doses and suitable outcome measures for a study, accounted for significant delays in the approval of new drugs by the Food and Drug Administration (FDA), according to a study in the January 22/29 issue of JAMA.

22 Jan 2014

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Vivaldi Biosciences Inc., a clinical-stage biotechnology company developing live attenuated influenza vaccines against seasonal and pandemic influenza, today announced that it has signed a Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to generate and evaluate in preclinical studies LAIV candidates against influenza A(H7N9).

21 Jan 2014

Gene therapy edges closer for Parkinson’s disease

Lentiviral vector-based gene therapy is well tolerated and may improve motor function in patients with Parkinson’s disease, shows an open-label study published in The Lancet.

20 Jan 2014

Viewpoints: Is overhaul really a 'war' on the young?; war on poverty requires spending; maternity leave in America

A long-shot lawsuit that could have damaged the effectiveness of health care reform got a well-deserved brushoff from a federal district judge on Wednesday.

20 Jan 2014

Findings suggest possible clinical uses of ecstasy in treating anxiety and PTSD

Brain imaging experiments have revealed for the first time how ecstasy produces feelings of euphoria in users.

17 Jan 2014

FDA approves New Drug Application for PENNSA 2%

Mallinckrodt today announced that the U.S. Food and Drug Administration has approved the New Drug Application for PENNSAID (diclofenac sodium topical solution) 2% w/w. PENNSAID 2% is a topical non-steroidal anti-inflammatory drug approved for use in the treatment of the pain of osteoarthritis of the knee(s).

17 Jan 2014

Continued use of statins may help prevent delirium in critically ill patients

Continued use of statins may help prevent delirium in critically ill patients who received statins before hospital admission, according to a new study of 470 intensive care patients in the UK.

17 Jan 2014

Robot-assisted therapy shows increased mobility after paresis

The survivors of a stroke often struggle with persistent loss of function of the central nervous system. Around the world strokes are one of the most frequent causes of paresis.

17 Jan 2014

Vitamin D may be adjunct for patients with fibromyalgia syndrome, say researchers

Patients with fibromyalgia syndrome (FMS) typically have widespread chronic pain and fatigue. For those with low vitamin D levels, vitamin D supplements can reduce pain and may be a cost-effective alternative or adjunct to other treatment, say researchers in the January 2014 issue of PAIN-.

17 Jan 2014

Longer reads: Connecting with patients; obesity origins; children with chronic disease

I'd never [before] been encouraged to sit at a patient's bedside - to stop hurrying for even a moment. Our medical teachers put a premium on accuracy and efficiency, which became conflated with speed.

17 Jan 2014

Traditional Chinese herbal medicines hold promise for slowing progression of diabetes

Traditional Chinese herbal medicines hold promise for slowing the progression from prediabetes to an official diabetes diagnosis, according to new research accepted for publication in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

17 Jan 2014

New way to improve lipid profiles in patients undergoing hemodialysis may prevent heart attack

Researchers at Wayne State University have discovered a potential way to improve the lipid profiles in patients undergoing hemodialysis that may prevent cardiovascular disease common in these patients.

16 Jan 2014

FDA accepts Iroko Pharmaceuticals' ZORVOLEX sNDA for review

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced that the U.S. Food and Drug Administration has accepted for review the Supplemental New Drug Application for ZORVOLEX (diclofenac), a lower dose nonsteroidal anti-inflammatory drug, for the proposed indication of treatment of osteoarthritis pain in adults. ZORVOLEX was approved by FDA in October 2013 for the treatment of mild to moderate acute pain in adults.

15 Jan 2014

Placebo News and Research

Pfizer announces results from Phase 3 study of ALO-02 in patients with chronic low back pain

Use of twice-daily pill could turn deadly blood cancer into highly treatable disease

Prosonix announces positive top-line results from PSX1002 Phase 2 study for COPD treatment

New drug helps children and young adults who have severe pain from sickle cell disease

Hydroxytyrosol in olive oil may help reduce risk of breast cancer

EnVivo Pharmaceuticals starts encenicline Phase 3 study in patients with Alzheimer's disease

Study shows clinical trials used by FD to approve new drugs vary widely in characteristics

Potentially preventable deficiencies account for significant delays in approval of new drugs by FDA

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Gene therapy edges closer for Parkinson’s disease

Viewpoints: Is overhaul really a 'war' on the young?; war on poverty requires spending; maternity leave in America

Findings suggest possible clinical uses of ecstasy in treating anxiety and PTSD

FDA approves New Drug Application for PENNSA 2%

Continued use of statins may help prevent delirium in critically ill patients

Robot-assisted therapy shows increased mobility after paresis

Vitamin D may be adjunct for patients with fibromyalgia syndrome, say researchers

Longer reads: Connecting with patients; obesity origins; children with chronic disease

Traditional Chinese herbal medicines hold promise for slowing progression of diabetes

New way to improve lipid profiles in patients undergoing hemodialysis may prevent heart attack

FDA accepts Iroko Pharmaceuticals' ZORVOLEX sNDA for review

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News